<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575636</url>
  </required_header>
  <id_info>
    <org_study_id>NL72424.068.19</org_study_id>
    <nct_id>NCT04575636</nct_id>
  </id_info>
  <brief_title>MRL in the Upper Extremity</brief_title>
  <official_title>Magnetic Resonance Lymphography in Upper Extremity Lymphedema and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The aim of this study is to examine the feasibility and applicability of the MRL&#xD;
      protocol for the upper extremity in Maastricht University Medical Center, and to examine the&#xD;
      differences of the lymphatic system between lymphedema patients and healthy volunteers.&#xD;
&#xD;
      Study design: An explorative study of an MRL protocol for the upper extremity in Maastricht&#xD;
      University Medical Center+.&#xD;
&#xD;
      Study population: There are two study groups. The first group (n=10) consists of patients&#xD;
      with secondary lymphedema in the upper extremity. The second group (n=10) consists of healthy&#xD;
      volunteers.&#xD;
&#xD;
      Intervention (if applicable):&#xD;
&#xD;
      All participants will undergo an MRL examination with the same protocol, developed in a&#xD;
      previous 'proof of principle' study, in the Maastricht University Medical Center+.&#xD;
&#xD;
      After localizer scans, a T2-weighted sequence is used. Then a T1-weighted sequence will be&#xD;
      made before the injection of contrast. After the injection of the contrast agent a&#xD;
      T1-weighted sequences of the upper and lower arm are performed alternately.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The primary outcome is to determine the feasibility and applicability of the MRL protocol by&#xD;
      evaluating the images of the upper extremity in patients with secondary lymphedema and&#xD;
      healthy subjects.&#xD;
&#xD;
      The secondary outcome is to assess the value of MRL in staging lymphedema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasiblity of Magentic Resonance Lymphography (MRL) of the arm by evaluating the MRL output images</measure>
    <time_frame>0.5 hours per participant</time_frame>
    <description>Describing lymphatic vessel characteristics in terms of size, diameter and course, and lymphedema symptoms such as dermal backflow or obstruction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lymphedema staging by evaluating the MRL output images</measure>
    <time_frame>0.5 hours per participant</time_frame>
    <description>Describing lymphedema stage, based on lymphatic vessel charasteristics and lymphedema symptoms as found at primary outcome. This is compared with ISL (clinical) lymphedema stage and ICG lymphography stage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphedema of Upper Limb</condition>
  <arm_group>
    <arm_group_label>Lymphedema patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MRL examination in lymphedema patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MRL examination in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Lymphography</intervention_name>
    <description>Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Lymphedema patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  BMI &lt; 30 kg/m2&#xD;
&#xD;
        Group A:&#xD;
&#xD;
        - Secondary lymphedema in the upper extremity&#xD;
&#xD;
        Group B:&#xD;
&#xD;
        - Healthy volunteers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active skin infection/erysipelas in the arm.&#xD;
&#xD;
          -  Known allergy for a contrast agent&#xD;
&#xD;
          -  History of surgical intervention in the arm.&#xD;
&#xD;
          -  Contraindications for MRI with contrast; pregnancy, metals, prostheses, renal&#xD;
             insufficiency, claustrophobia&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Distant metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joost Wolfs, MD</last_name>
    <phone>043 387 2308</phone>
    <email>joost.wolfs@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scannexus</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Wolfs, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

